Search hospitals
>
Michigan
>
Ann Arbor
University of Michigan Comprehensive Cancer Center
Claim this profile
Ann Arbor, Michigan 48109
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Pancreatic Cancer
856 reported clinical trials
60 medical researchers
Summary
University of Michigan Comprehensive Cancer Center is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. University of Michigan Comprehensive Cancer Center is involved with conducting 856 clinical trials across 636 conditions. There are 60 research doctors associated with this hospital, such as Paul Swiecicki, Rashmi Chugh, MD, Vaibhav Sahai, MBBS, MS, and Francis P. Worden.
Area of expertise
Breast Cancer
University of Michigan Comprehensive Cancer Center has run 108 trials for Breast Cancer. Some of their research focus areas include:
Cancer
University of Michigan Comprehensive Cancer Center has run 90 trials for Cancer. Some of their research focus areas include:
Top PIs
Paul Swiecicki
University of Michigan Comprehensive Cancer Center
6 years of reported clinical research
Rashmi Chugh, MD
University of Michigan
6 years of reported clinical research
Vaibhav Sahai, MBBS, MS
University of Michigan Comprehensive Cancer Center
6 years of reported clinical research
Francis P. Worden
University of Michigan
6 years of reported clinical research
Clinical Trials running at University of Michigan Comprehensive Cancer Center
Breast Cancer
Cancer
Skin Cancer
Breast cancer
Kidney Cancer
Prostate Cancer
Lung Cancer
Pancreatic Cancer
Ovarian Cancer
Testicular cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Recruiting
2 awards
Phase 3
23 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting
2 awards
Phase 3
12 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting
2 awards
Phase 3
8 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Michigan Comprehensive Cancer Center?
University of Michigan Comprehensive Cancer Center is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and other specialties. University of Michigan Comprehensive Cancer Center is involved with conducting 856 clinical trials across 636 conditions. There are 60 research doctors associated with this hospital, such as Paul Swiecicki, Rashmi Chugh, MD, Vaibhav Sahai, MBBS, MS, and Francis P. Worden.
Where is University of Michigan Comprehensive Cancer Center located?
To reach the University of Michigan Comprehensive Cancer Center in Ann Arbor from US-23 North, use the Washtenaw Ave./BR23 exit (#37B). From US-23 South, take the Plymouth Road exit (#41). Follow the signs to Medical Center Drive where the Cancer Center is located. Parking is available in Structure P1, adjacent to the Cancer Center, for patients and their families.
Who should I call to ask about financial aid or insurance network?
The University of Michigan Comprehensive Cancer Center provides financial assistance and insurance support, including a financial assistance program offering a 60% discount for uninsured patients, potentially qualifying for free care for certain services. Patients can apply by downloading the application form available in multiple languages. For insurance matters, the center accepts most plans and advises patients to verify coverage with their health plan before scheduling appointments. Assistance with expenses, transportation, and billing questions is available through the Patient Assistance Center, reachable at 855-855-0863 or 734-615-0863, Monday - Friday, 8:30 a.m. - 6 p.m.
What insurance does University of Michigan Comprehensive Cancer Center accept?
The University of Michigan Comprehensive Cancer Center accepts a wide range of insurance plans, including Medicare, Medicaid, Blue Cross Blue Shield of Michigan (BCBSM), Blue Care Network (BCN), among others. Accepted insurance plans may vary by service type, including laboratory services and cancer treatment. For the most current information on accepted insurance, please contact the hospital directly.
What awards or recognition has University of Michigan Comprehensive Cancer Center received?
The University of Michigan Rogel Cancer Center, located in Ann Arbor, Michigan, is distinguished as a comprehensive cancer center by the National Cancer Institute (NCI), receiving a $37 million grant for research across basic science, translational research, clinical research, and population sciences. It holds recognition from the Quality Oncology Practice Initiative (QOPI®) and is part of the Michigan Cancer Consortium, the Big Ten Cancer Research Consortium, and the Commission on Cancer (CoC) of the American College of Surgeons.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.